Metabolomics in the Development and Progression of Dementia: A Systematic Review

Frontiers in Neuroscience

Weimin Ye¹  Yanfeng Jiang²  Xingdong Chen³  Li Jin³  Jie Shi⁴  Yingzhe Wang⁴  Mei Cui⁴  Shuyuan Li⁵  Zhen Zhu⁶  Kexun Zhang⁶  Yanpeng An⁸ 

[1] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden;Fudan University Taizhou Institute of Health Sciences, Taizhou, China;Human Phenome Institute, Fudan University, Shanghai, China;Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, China;International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China;Key Laboratory of Public Health Safety of Ministry of Education, Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China;State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China;State Key Laboratory of Genetic Engineering, Metabonomics and Systems Biology Laboratory, School of Life Sciences, Fudan University, Shanghai, China;

关键词: metabolomics;    lipidomics;    metabolites;    dementia;    Alzheimer's disease;    mild cognitive impairment;   

DOI  :  10.3389/fnins.2019.00343

来源: DOAJ

【 摘 要 】

Dementia has become a major global public health challenge with a heavy economic burden. It is urgently necessary to understand dementia pathogenesis and to identify biomarkers predicting risk of dementia in the preclinical stage for prevention, monitoring, and treatment. Metabolomics provides a novel approach for the identification of biomarkers of dementia. This systematic review aimed to examine and summarize recent retrospective cohort human studies assessing circulating metabolite markers, detected using high-throughput metabolomics, in the context of disease progression to dementia, including incident mild cognitive impairment, all-cause dementia, and cognitive decline. We systematically searched the PubMed, Embase, and Cochrane databases for retrospective cohort human studies assessing associations between blood (plasma or serum) metabolomics profile and cognitive decline and risk of dementia from inception through October 15, 2018. We identified 16 studies reporting circulating metabolites and risk of dementia, and six regarding cognitive performance change. Concentrations of several blood metabolites, including lipids (higher phosphatidylcholines, sphingomyelins, and lysophophatidylcholine, and lower docosahexaenoic acid and high-density lipoprotein subfractions), amino acids (lower branched-chain amino acids, creatinine, and taurine, and higher glutamate, glutamine, and anthranilic acid), and steroids were associated with cognitive decline and the incidence or progression of dementia. Circulating metabolites appear to be associated with the risk of dementia. Metabolomics could be a promising tool in dementia biomarker discovery. However, standardization and consensus guidelines for study design and analytical techniques require future development.

【 授权许可】

Unknown